Skip to content
Poster

Cardiorenal protective effects of semaglutide in a mouse model of hypertension-accelerated diabetic kidney disease

Background & Aim:

Obesity, hyperglycemia and hypertension are critical risk factors for the development of diabetic cardiovascular disease (CVD) and diabetic kidney disease (DKD). Emerging evidence suggests that glucagon-like peptide-1 receptor agonists (GLP-1RAs) improve cardiovascular and renal outcomes in type 2 diabetic patients. Here, we characterized the cardiovascular effects of semaglutide, a long-acting GLP-1RA, in a mouse model of hypertension-accelerated advanced DKD, facilitated by adeno-associated virus-mediated renin overexpression (ReninAAV) in uninephrectomized (UNx) female diabetic db/db mice.

Subjects
Cardiovascular disease3D imagingAdeno-associated virus (AAV)-mediated gene deliveryReninAAV UNx db/db mouseCardiovascular diseaseMouseBody weightBlood biochemistryDiabetic kidney diseaseGLP-1 receptorHistopathology scoreImage analysisImmunohistochemistry (IHC)Light sheet fluorescence microscopy (LSFM)Urine biochemistrySemaglutide

For further information

Contact us

Gubra

Hørsholm Kongevej 11B
2970 Hørsholm
Denmark

+45 3152 ­2650

Back To Top